The MIDD has worked with several local startup companies. Some of these companies were founded after significant research was conduced in collaboration with the MIDD. The Institute offers fee for service to companies that have limited research space or are interested in specific services. The industry projects are supported by academic research groups. This format provides valuable industry experience for students and hiring opportunities for companies.
Estrigenix
Estrigenix’s lead compound selectively binds the estrogen receptor beta receptor and is currently in development for hot flashes and dementia. (William Donaldson, CEO)
T3 Bioscience
T3 Bioscience is developing new anti-pathogens based on bacteria and small molecules. (Daniel Burgin, CEO)
Function Therapeutics
Function Therapeutics develops anti-inflammatory agents called parmodulins, which interact with protease-activated receptor 1. (Chris Dockendorff, CEO)
Focuses on the develop an animal model of chronic fatigue syndrome and subsequent treatments. (Gunnar Gottschalk and Avik Roy)
Focuses on the development of small molecule cancer treatments. (Taufeeque Ali, CEO)
Targeting STAT3 for novel cancer treatments. (Avik Roy, CEO)
Elafar Therapeutics
Development of a novel HDACi for increased memory performance in neurodegenerative diseases. (Mahmun Hossain, CEO)
Development of new therapies to reverse diabetic cardiovascular disease. (Michael Widlansky, CEO)